Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 2 2000
Play
Audio Below:
I’m
now more convinced than ever that the women who really benefit from
tamoxifen are the ones who have some change in menstrual function.
And those data certainly suggested to me that if you became postmenopausal,
either by chemotherapy or by Zoladex, tamoxifen was going to work
much better, than if you were still actively menstruating. So, that’s
just another reason to do and make certain that the patient is postmenopausal
before you start your tamoxifen. And I think that a woman who was
premenopausal, became postmenopausal, and then gets tamoxifen, –
assuming now she has an ER-positive tumor – is going to get
a lot more benefit. And the tamoxifen then has just the same benefit
in that group of women as in postmenopausal women.
Relevant
Articles:
Combined
endocrine therapy for breast cancer - New life for an old idea?
Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute. 92(11):859-860, 2000 Jun 7. No
abstract
